INKT MINK THERAPEUTICS INC

MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference

MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference

NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the HC Wainwright Cell Therapy Virtual Conference on February 28th, at 9:00 AM ET.

Access to the live fireside chat is available at . Following the fireside chat, a replay will be available on the Events and Presentations page of the MiNK website at .

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit . Follow us on Twitter @MiNK_iNKT.

Contact

Alexa Buffa

781-674-4428

Investor relations:

Zack Armen

917-362-1370



EN
16/02/2023

Underlying

INKTMINK THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MINK THERAPEUTICS INC

 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second...

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant to advance INKTs in GVHD announced; program advancingNew clinical grant awarded to launch AgenT-797 in GvHD clinical trial; target initiation 2H2025 NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announc...

10h / 47m 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 F...

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its second quarter 2025 financial results before the market opens on Thursday, August 14, 2025. MiNK executives will host a conference call and ...

July 31, 2025 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Announces Frontiers in Immunology Publication Highli...

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy iNKT cells uniquely remodel the tumor microenvironment, overcome immune resistance, and enable scalable off-the-shelf cell therapy NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies, today announced the publication of a peer-reviewed article titled “CAR-iNKT Cells: Redefinin...

July 15, 2025 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Announces Publication of Complete Remission Followin...

MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced the publication of another landmark case in , following treatment with agenT-797, MiNK’s allogeneic iNKT cell therapy. Complete remission after ...

July 11, 2025 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 18, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit  and enter the 16-digit control numbe...

June 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch